Title :

Borderline Personality Disorder and Oxytocin: Review of Clinical Trials and Future Directions

Author(s) :

Amad, Ali [Auteur]
Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 [SCALab]
Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 [SCALab]
Thomas, Pierre [Auteur]
Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 [SCALab]
Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 [SCALab]
Perez-Rodriguez, M. Mercedes [Auteur]

Journal title :

Current Pharmaceutical Design

Abbreviated title :

Curr. Pharm. Des.

Volume number :

21

Pages :

3311-3316

Publication date :

2015

ISSN :

1873-4286

HAL domain(s) :

Sciences cognitives

English abstract : [en]

Borderline personality disorder (BPD) is a common mental disorder characterized by a pervasive pattern of emotional Borderline personality disorder (BPD) is a common mental disorder characterized by a pervasive pattern of ...
Show more >Borderline personality disorder (BPD) is a common mental disorder characterized by a pervasive pattern of emotional Borderline personality disorder (BPD) is a common mental disorder characterized by a pervasive pattern of emotional lability, impulsivity, interpersonal difficulties, identity disturbances, and disturbed cognition. Traditional pharmacotherapies are effective in treating some of these core symptoms but have only modest effects on the domain of interpersonal dysfunction of BPD. Thus there is a need to develop new, neurobiologically informed pharmacological treatments for BPD. This review focuses on the potential use of intranasal oxytocin (OXT), which has key roles in the regulation of complex social cognition and behaviors, to target symptoms of interpersonal dysfunction in BPD. Surprisingly, despite promising data on the prosocial effects of OXT, only 5 trials in BPD have been published to date. These trials show mixed results with on one hand, a decrease of emotional responses to stress and on the other hand, some "paradoxical" reactions with worsened interpersonal anxiety and decreased cooperative behavior. These mixed results are interpreted according to different theoretical models and also in light of some methodological limitations. Further studies are needed to understand the effect of OXT in patients with BPD and ongoing clinical trials will provide some answers to remaining questions on the use of OXT in BPD. Recommendations for future studies are also proposed in this review.Show less >

Language :

Anglais

Audience :

Non spécifiée

Administrative institution(s) :

Université de Lille
CNRS
CHU Lille

Collections :

• Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193

Research team(s) :

Équipe Psychiatrie & Croyance (PsyCHIC)

Submission date :

2019-02-13T14:50:54Z
2019-11-26T16:18:21Z